drugset
drugset / Trial / NCT03261739

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT03261739 ↗

Phase 1 Completed 84 enrolled Bird Rock Bio, Inc. Perspectum · collabProSciento, Inc. · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.

Timeline

Start
2017-08-28
Primary completion
2018-08-24
Completion
2018-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimacimab Monoclonal antibody 0.6 mg/kg Intravenous
Subject Nimacimab Monoclonal antibody 1.2 mg/kg Intravenous
Subject Nimacimab Monoclonal antibody 2.5 mg/kg Intravenous

Indications

fatty liver disease